全文获取类型
收费全文 | 15072篇 |
免费 | 1180篇 |
国内免费 | 550篇 |
专业分类
耳鼻咽喉 | 66篇 |
儿科学 | 169篇 |
妇产科学 | 149篇 |
基础医学 | 785篇 |
口腔科学 | 593篇 |
临床医学 | 1456篇 |
内科学 | 2644篇 |
皮肤病学 | 392篇 |
神经病学 | 503篇 |
特种医学 | 643篇 |
外科学 | 1526篇 |
综合类 | 1541篇 |
现状与发展 | 1篇 |
预防医学 | 789篇 |
眼科学 | 149篇 |
药学 | 3996篇 |
4篇 | |
中国医学 | 179篇 |
肿瘤学 | 1217篇 |
出版年
2023年 | 182篇 |
2022年 | 264篇 |
2021年 | 508篇 |
2020年 | 518篇 |
2019年 | 541篇 |
2018年 | 545篇 |
2017年 | 525篇 |
2016年 | 583篇 |
2015年 | 623篇 |
2014年 | 868篇 |
2013年 | 1566篇 |
2012年 | 875篇 |
2011年 | 932篇 |
2010年 | 719篇 |
2009年 | 694篇 |
2008年 | 710篇 |
2007年 | 713篇 |
2006年 | 575篇 |
2005年 | 602篇 |
2004年 | 487篇 |
2003年 | 458篇 |
2002年 | 382篇 |
2001年 | 315篇 |
2000年 | 260篇 |
1999年 | 200篇 |
1998年 | 162篇 |
1997年 | 201篇 |
1996年 | 124篇 |
1995年 | 151篇 |
1994年 | 130篇 |
1993年 | 136篇 |
1992年 | 115篇 |
1991年 | 114篇 |
1990年 | 93篇 |
1989年 | 92篇 |
1988年 | 90篇 |
1987年 | 95篇 |
1986年 | 73篇 |
1985年 | 80篇 |
1984年 | 79篇 |
1983年 | 60篇 |
1982年 | 57篇 |
1981年 | 45篇 |
1980年 | 44篇 |
1979年 | 41篇 |
1978年 | 38篇 |
1977年 | 28篇 |
1976年 | 32篇 |
1974年 | 16篇 |
1973年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
The seventh leading cause of cancer-related death globally, pancreatic ductal adenocarcinoma (PDAC) involves the exocrine pancreas and constitutes greater than 90% of all pancreatic cancers. Surgical resection in combination with systemic chemotherapy with or without radiation remains the mainstay of treatment and the only potentially curative treatment option. While there has been improvement in systemic chemotherapy, long-term survival among patients with PDAC remains poor. Improvement in the understanding of tumorigenesis, genetic mutations, the tumor microenvironment (TME), immunotherapies, as well as targeted therapies continued to drive advances in PDAC treatment. We herein review the TME, genetic landscape, as well as various metabolic pathways associated with PDAC tumorigenesis relative to emerging therapies. 相似文献
2.
3.
[摘要] 目的 评估直接抗病毒药物(direct antivirus agent, DAA)治疗肝移植术后HCV感染复发的有效性和安全性。方法?回顾性分析首都医科大学附属北京佑安医院2011年2月—2018年12月收治的14例肝移植术后HCV感染复发患者的DAA治疗临床数据,比较患者基线与治疗结束后肝肾功能、血常规、凝血功能、病毒学水平以及无创纤维化评分天冬氨酸转氨酶血小板比率指数(aspartate aminotransferase-platelet ratio index, APRI)的差异。利用电子病历系统和电话随访收集患者治疗期间不良反应发生情况。结果?所有患者均在治疗结束时达到病毒学清除,12周、24周持续病毒学应答率均为100%,DAA治疗后随访17~44个月,期间均未见病毒学复发。与基线水平相比,治疗终点时ALT、AST、TBIL、γ-谷氨酰转移酶以及无创纤维化评分APRI显著下降,WBC、HGB、PLT、CRE、肾小球滤过率和血糖等指标均未见显著变化。DAA治疗期间共3例患者发生不良反应,均为轻度,可自然缓解。结论?肝移植术后HCV感染复发的DAA治疗是安全有效的。 相似文献
4.
5.
6.
《Revista de gastroenterologia de Mexico》2022,87(1):52-58
IntroductionThe sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12 weeks post-treatment a relevant undertaking.MethodsA retrospective review of the case records of 241 patients seen at 20 hospitals in Mexico was conducted to assess hepatitis C treatment with the SOF/VEL combination (n = 231) and the sofosbuvir/velpatasvir/ribavirin (SOF/VEL/RBV) combination (n = 10). The primary efficacy endpoint was the percentage of patients that achieved SVR at 12 weeks after the end of treatment.ResultsOverall SVR was 98.8% (95% CI 97.35-100%). Only three patients did not achieve SVR, two of whom had cirrhosis and a history of previous treatment with peg-IFN. Of the subgroups analyzed, all the patients with HIV coinfection, three patients with genotype 3, and the patients treated with the SOF/VEL/RBV combination achieved SVR. The subgroups with the lower success rates were patients that were treatment-experienced (96.8%) and patients with F1 fibrosis (95.5%). The most frequent adverse events were fatigue, headache, and insomnia. No serious adverse events were reported.ConclusionTreatments with SOF/VEL and SOF/VEL/RBV were highly safe and effective, results coinciding with those of other international real-world studies. 相似文献
7.
8.
9.
Anqi Wang Yan Xu Yunyun Fei Mengzhao Wang 《Asia-Pacific Journal of Clinical Oncology》2020,16(4):201-210
The advent of immune checkpoint inhibitors has improved survival in some types of cancer and brought promising prospects to cancer immunotherapy. Despite their clinical benefits, significant off‐target toxicities resulting from the immune system activation have been observed, namely immune‐related adverse events (irAEs), which pose to clinicians a new challenge of optimal management. With steroids being the mainstay of current management of irAEs, immunosuppressive agents are especially indicated for severe or steroid‐refractory cases, based on current immunopathophysiological knowledge and on extrapolations of treatment options for primary autoimmune disorders. This review focuses on the status and recent clinical progress of immunosuppressive agents in the management of severe and steroid‐refractory irAEs. 相似文献
10.